Chemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma
European Journal of Cancer2022Vol. 175, pp. 43–53
Citations Over TimeTop 20% of 2022 papers
Lucie Meynard, Derek Dinart, Blandine Delaunay, Aude Fléchon, Carolina Saldana, Félix Lefort, Gwénaëlle Gravis, Antoine Thiery-Vuillemin, Mathilde Cancel, Elodie Coquan, Sylvain Ladoire, Denis Maillet, Frédéric Rolland, Elouen Boughalem, Sophie Martin, Mathieu Laramas, Laurence Crouzet, Baptiste Abbar, Sabrina Falkowski, Damien Pouessel, Guilhem Roubaud
Related Papers
- → Atezolizumab for platinum-treated metastatic urothelial carcinoma(2017)11 cited
- → [Second-line treatment of metastatic urothelial carcinoma : Update immuno-oncology].(2020)5 cited
- → A Phase 3 study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs placebo + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC): IMvigor130(2019)4 cited
- → Comparison of response evaluation criteria in solid tumors (RECIST), European Association for the study of the liver (EASL) and modified RECIST criteria in evaluation of tumor response after transarteriai chemoembolization of primary liver cancer(2011)2 cited
- → Application of circulating tumor cells detection in chemotherapeutic efficacy evaluation of non-small cell lung cancer(2018)